Differentiation of Burkitt lymphoma cells by hexamethylenbisacetamide

Hexamethylenbisacetamide (HMBA) can induce the Burkitt lymphoma Raji cells to enter the differentiation process as evidenced by the decrease of HLA-DR antigens. This event is preceded by a decrease of c-myc expression and of the phosphorylation of cellular proteins, due to either a decrease of tyros...

Full description

Saved in:
Bibliographic Details
Published inMolecular biology reports Vol. 13; no. 3; p. 151
Main Authors Semmel, M, Hanania, N, Huet, S, Pavloff, N, Gay, F, Biquard, J M
Format Journal Article
LanguageEnglish
Published Netherlands 01.01.1989
Subjects
Acetamides - pharmacology
Animals
B-Lymphocytes - cytology
Burkitt Lymphoma
Cell Differentiation - drug effects
Cell Division - drug effects
HLA-DR Antigens - analysis
Immunoblotting
Nucleic Acid Hybridization
Phosphorylation
Protein-Tyrosine Kinases - metabolism
Proteins - metabolism
Proto-Oncogene Proteins - biosynthesis
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins c-myc
Tumor Cells, Cultured
Online AccessGet more information

Cover

More Information
Summary:Hexamethylenbisacetamide (HMBA) can induce the Burkitt lymphoma Raji cells to enter the differentiation process as evidenced by the decrease of HLA-DR antigens. This event is preceded by a decrease of c-myc expression and of the phosphorylation of cellular proteins, due to either a decrease of tyrosine protein kinase activity or an increase of tyrosine phosphatase activity. These three events form a sequence and are part of the genetic program for differentiation and growth though they may not be causally related.
ISSN:0301-4851
DOI:10.1007/BF00444311